United Therapeutics Corp
UTHR
Market Cap$11.1B
Close$
$362.78
40.5% upside
Current Fair Value
40.5% upsideUndervalued by 40.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $11.10 Billion |
|---|---|
| Enterprise Value | $8.81 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $19.81 |
| Beta | 0.0 |
| Outstanding Shares | 47,058,545 |
| Avg 30 Day Volume | 528,781 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 11.27 |
|---|---|
| PEG | 17.52 |
| Price to Sales | 5.27 |
| Price to Book Ratio | 2.03 |
| Enterprise Value to Revenue | 3.78 |
| Enterprise Value to EBIT | 7.43 |
| Enterprise Value to Net Income | 8 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 0.12 |
Revenue Sources
No data
ESG Score
No data
About United Therapeutics Corp
920 employees
CEO: Martine Rothblatt United Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model. We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and innovation, the power o...